From the Guidelines
WinRevAir is not mentioned in the provided evidence, and its use cannot be determined based on the given studies. The provided studies discuss the administration of anti-D immunoglobulin among Rh-negative women during the first trimester of pregnancy and the treatment of ectopic pregnancy with methotrexate 1.
- The studies do not provide any information about WinRevAir or its potential uses.
- The evidence focuses on pregnancy-related topics, such as threatened abortion, complete abortion, ectopic pregnancy, and minor abdominal trauma, and does not mention WinRevAir or any similar medication.
- Without relevant information, it is not possible to determine the use of WinRevAir based on the provided studies.
- Further research or evidence would be necessary to understand the purpose and application of WinRevAir, considering its potential impact on morbidity, mortality, and quality of life.
From the Research
What is Winrevair used for
- Winrevair, also known as sotatercept, is used for the treatment of adults with pulmonary arterial hypertension (PAH) Group 1, on top of background PAH therapy 2, 3, 4
- The primary goal of using Winrevair is to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events in patients with PAH 2, 3, 4
- Winrevair works by sequestering free activins, which helps to restore the balance between the activin proliferative pathway and the bone morphogenic protein (BMP) antiproliferative pathway in the pulmonary arterial circulation 2
- Winrevair has been shown to significantly improve the 6-min walk distance in patients with PAH after 24 weeks, with a mean change increase of 40.1 meters in the experimental group versus 1.4 meters decrease in the placebo group 3
- Common adverse events associated with Winrevair include epistaxis, telangiectasia, increased hemoglobin, hematocrit, red blood cell levels, and dizziness 3, 4